Anika Therapeutics ANIK Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Anika Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Anika Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Anika Therapeutics's financing cash flow?
- Anika Therapeutics (ANIK) reported financing cash flow of -$10.35M in Q1 2026.
- How has Anika Therapeutics's financing cash flow changed year-over-year?
- Anika Therapeutics's financing cash flow decreased by 90.3% year-over-year, from -$5.44M to -$10.35M.
- What is the long-term trend for Anika Therapeutics's financing cash flow?
- Over 3 years (2021 to 2025), Anika Therapeutics's financing cash flow has grown at a 16.2% compound annual growth rate (CAGR), from -$6.84M to -$10.73M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.